2. Search Result
Search Result
Results for "

HDAC6 degrader

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132998
    HDAC6 degrader-1

    		PROTACs Others
    HDAC6 degrader-1 is a PROTAC that comprises a selective HDAC6 inhibitor Nexturastat A (Nex A) as the HDAC6 binder, a linker and a ligand for recruiting E3 ligase. HDAC6 degrader-1 induces significant degradation of HDAC6, exhibits excellent selectivity against other HDACs, and demonstrates efficient inhibition of cell proliferation .
    HDAC6 degrader-1
  • HY-152134
    HDAC6 degrader-3

    		HDAC PROTACs Cancer
    HDAC6 degrader-3 is a potent and selective HDAC6 degrader via ternary complex formation and the ubiquitin-proteasome pathway with a DC50 value of 19.4 nM. HDAC6 degrader-3 has IC50s of 4.54 nM and 0.647 μM for HDAC6 and HDAC1, respectively. HDAC6 degrader-3 causes strong hyperacetylation of α-tubulin .
    HDAC6 degrader-3
  • HY-171140
    PROTAC HDAC6 degrader 3

    		PROTACs HDAC Cancer
    PROTAC HDAC6 degrader 3 (Compound 4) is a selective inhibitor and degrader for HDAC6 with an IC50 of 686 nM and a DC50 of 171 nM. PROTAC HDAC6 degrader 3 promotes the acetylation of α-tubulin . (Pink: ligand for target protein (HY-171141); Blue: ligand for E3 ligase VHL (HY-150803))
    PROTAC HDAC6 degrader 3
  • HY-171141
    HDAC6 ligand-2

    		Ligands for Target Protein for PROTAC HDAC Cancer
    HDAC6 ligand-2 (Compound 15) is the ligand for HDAC6 that can be used for synthesis of PROTAC HDAC6 degrader 2 (HY-171139) .
    HDAC6 ligand-2
  • HY-123971
    HDAC6 degrader-4

    		HDAC PROTACs Cancer
    HDAC6 degrader-4 is a PROTAC and a selective HDAC6 degrader consists of a non-selective HDAC inhibitor and thalidomide-type E3 ligase ligand. HDAC6 degrader-4 can be used for cancer research .
    HDAC6 degrader-4
  • HY-170495
    HDAC6 degrader-5

    		HDAC Apoptosis Interleukin Related Inflammation/Immunology
    HDAC6 degrader-5 (Compound 6) exhibits inhibitory and degradation activity against HDAC6, with an IC50 of 4.95 nM and a DC50 of 0.96 nM. HDAC6 degrader-5 inhibits the release of TNF-α, IL-1β and IL-6, blocks the hepatocyte apoptosis. HDAC6 degrader-5 exhibits anti-inflammatory activity in mouse APAP (HY-66005)-induced liver injury models .
    HDAC6 degrader-5
  • HY-171139
    PROTAC HDAC6 degrader 2

    		PROTACs HDAC Cancer
    PROTAC HDAC6 degrader 2 (Compound 1) is a HDAC6 PROTAC degrader, with IC50 of 0.643 μM. PROTAC HDAC6 degrader 2 promotes ubiquitination and degradation of HDAC6. PROTAC HDAC6 degrader 2 can be used for the research of haematological and solid cancers (Pink: HDAC6 ligand (HY-171141); Blue: E3 ligase CRBN ligand (HY-10984)) .
    PROTAC HDAC6 degrader 2
  • HY-152133
    PROTAC HDAC6 degrader 1

    		PROTACs HDAC Apoptosis Cancer
    PROTAC HDAC6 degrader (Compound A6) is a potent and selective PROTAC HDAC6 degrader with a DC50 of 3.5 nM. PROTAC HDAC6 degrader shows promising antiproliferative activity via inducing apoptosis in myeloid leukemia cell lines .
    PROTAC HDAC6 degrader 1
  • HY-172359
    PROTAC HDAC6 degrader 4

    		PROTACs HDAC Cancer
    PROTAC HDAC6 degrader 4 (Compound 17c) is the PROTAC degrader for HDAC6 with a DC50 of 14 nM. PROTAC HDAC6 degrader 4 exhibits inhibitory activit against HDAC1, HDAC2, HDAC3 and HDAC6 with IC50s of 2.2, 2.37, 0.61 and 0.295 μM, respectively . (Pink: ligand for target protein HDAC6 ligand-3 (HY-172360); Black: linker (HY-138387); Blue: ligand for cereblon E3 ligase (HY-W093272))
    PROTAC HDAC6 degrader 4
  • HY-172360
    HDAC6 ligand-3

    		HDAC Ligands for Target Protein for PROTAC Cancer
    HDAC6 ligand-3 is a ligand for HDAC6 that can be used as target protein ligand for synthesis of PROTAC HDAC6 degrader 4 (HY-172359) .
    HDAC6 ligand-3
  • HY-155396
    PRO-HD1

    		PROTACs HDAC Cancer
    PRO-HD1 is a PROTAC HDAC6 degrader. PRO-HD1 degrades HDAC6 in A549 cells, and inhibits proliferation of Jurkat cells (IC50: 5.8 μM) .
    PRO-HD1
  • HY-173266
    TO-1187

    		PROTACs HDAC Neurological Disease Cancer
    TO-1187 is a selective HDAC6 PROTAC degrader (DC50: 5.81 nM). TO-1187 promotes the ubiquitination and degradation of HDAC6 and can be used in the study of hematological malignancies and solid tumors (Pink: HDAC6 ligand (HY-173386); Blue: CRBN ligand (HY-41547); Black: linker (HY-140212)) .
    TO-1187
  • HY-155398
    PRO-HD3

    		PROTACs HDAC Cancer
    PRO-HD3 is a cell-specific, PROTAC-based HDAC6 degrader .
    PRO-HD3
  • HY-155397
    PRO-HD2

    		PROTACs HDAC Cancer
    PRO-HD2 is a cell-specific, PROTAC-based HDAC6 degrader .
    PRO-HD2
  • HY-126147
    J22352

    		HDAC Cancer
    J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1 .
    J22352
  • HY-172361
    Thalidomide-F-NH-C6-adize

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Thalidomide-F-NH-C6-adize is the conjugate of an E3 ligase (Cereblon) ligand and a linker, and can be used for synthesis of PROTAC HDAC6 degrader 4 (HY-172359) .
    Thalidomide-F-NH-C6-adize
  • HY-159172
    HDAC3-IN-4

    		HDAC Cancer
    HDAC3-IN-4 is a selective and orally active HDAC3 inhibitor with an IC50 of 89 nM. HDAC3-IN-4 induces the degradation of PD-L1 by regulating cathepsin B (CTSB) in the lysosomes, with a DC50 of 5.7 μM. HDAC3-IN-4 shows better selectivity for HDAC3 over HDAC1, HDAC6, HDAC7, and HDAC8 .
    HDAC3-IN-4
  • HY-172159
    FF2039

    		HDAC Apoptosis Cancer
    FF2039 (compound 1j) is a specific HDAC1, HDAC6, and HDAC isoforms of class I, IIa and IIb PROTAC degrader. FF2039 demonstrates s significant antiproliferative activity against both hematological and solid cancer cell lines, driven by cell cycle arrest and Apoptosis induction. FF2039 inhibits HDAC isoform of HDAC1, HDAC2, HDAC4 and HDAC6 with IC50s of 1.03, 2.15, 12.4 and 0.053 μM, respectively. FF2039 shows antiproliferative activity against different tumor entities of MM.1S, MDA-MB-231 and U-87MG with EC50s of 2.8, 28 and 30 μM, respectively. (Pink: PRMT5 ligand (HY-168864); Blue: E3 ligase ligand HY-W957284); Black: linker (HY-W881439); E3+linker (HY-172185 )) .
    FF2039
  • HY-168175
    PROTAC HDAC8 Degrader-2

    		PROTACs HDAC Cancer
    PROTAC HDAC8 Degrader-2 (compound 32a) is a degrader of HDAC8 with a DC50 of 8.9 nM and HDAC6 with a DC50 of 14.3 nM. PROTAC HDAC8 Degrader-2 is composed of PROTAC target protein ligand HDAC8 ligand 1 (HY-168176) (red part), E3 ligase ligand Thalidomide-4-OH (HY-103596) (blue part) and PROTAC Linker 1,5-Diaminopentane (HY-W540541) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C5-NH2 (HY-134986) .
    PROTAC HDAC8 Degrader-2